LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

24.5 -1.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.28

Максимум

25.29

Ключови измерители
By Trading Economics
Приходи	10M 17M
Продажби	30M 130M
EPS	0.13
Марж на печалбата	13.432
Служители	354
EBITDA	11M 22M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+38.32% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-144M 3.1B
Предишно отваряне	25.71
Предишно затваряне	24.5

Настроения в новините

By Acuity

35%

65%

90 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2026 г., 20:38 ч. UTC

Печалби

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10.03.2026 г., 23:06 ч. UTC

Печалби

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10.03.2026 г., 22:51 ч. UTC

Значими събития в новините

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10.03.2026 г., 21:21 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10.03.2026 г., 21:15 ч. UTC

Печалби

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10.03.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10.03.2026 г., 21:14 ч. UTC

Печалби

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10.03.2026 г., 21:13 ч. UTC

Печалби

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q Rev $597.3M >FNV

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q EPS $1.90

10.03.2026 г., 20:57 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

10.03.2026 г., 20:44 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10.03.2026 г., 20:23 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:16 ч. UTC

Печалби

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10.03.2026 г., 20:13 ч. UTC

Печалби

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10.03.2026 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

38.32% нагоре

12-месечна прогноза

Среден 34.33 USD 38.32%

Висок 36 USD

Нисък 31 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

90 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.